Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say
For the quarter ended September 2023, Revance Therapeutics, Inc. (RVNC) reported revenue of $56.78 million, up 95.6% over the same period last year. EPS came in at -$0.74, compared to -$1.17 in the year-ago quarter.
The reported revenue represents a surprise of -2.92% over the Zacks Consensus Estimate of $58.49 million. With the consensus EPS estimate being -$1.02, the EPS surprise was +27.45%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Revance Therapeutics, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Service revenue: $2.66 million versus $3.30 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +35.6% change.
Revenue- Product revenue: $54.11 million versus the five-analyst average estimate of $57.90 million. The reported number represents a year-over-year change of +107.5%.
Revenue- Collaboration revenue: $0 million compared to the $0.62 million average estimate based on two analysts.
View all Key Company Metrics for Revance Therapeutics, Inc. here>>>
Shares of Revance Therapeutics, Inc. have returned -16.7% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Revance Therapeutics, Inc. (RVNC) : Free Stock Analysis Report
